The Hallmarks of BPH Progression and Risk Factors

European Urology, Supplement

Volumn 2, Issue 8, 2003, Pages 2-7

  Emberton, M ^a  

^a INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

Author keywords

Age; BPH; Disease progression; PSA; Quality of life; Risk factors

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE;

AGE DISTRIBUTION; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; HUMAN; MEDICAL LITERATURE; POPULATION RESEARCH; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RISK FACTOR; TUMOR GROWTH; URINE RETENTION;

EID: 0344445397     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2003.09.008     Document Type: Conference Paper

References (21)

1. Jacobsen SJ, Girman CJ, Guess HA, Oesterling JE, Lieber MM. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Arch Intern Med 1995;155:477-81.
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132: 474-9.
3. Emberton M, Andriole GL, de la Rosette J, Djavan B, Hoefner K, Vela Navarrette R, et al. BPH: a progressive disease of the ageing male. Urology 2003;61(2):267-73.
4. Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM. Natural history of prostatism: Longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996; 155:595-600.
5. Roberts RO, Jacobsen SJ, Jacobsen DJ, Rhodes T, Girman CJ, Lieber MM. Longitudinal changes in peak urinary flow rates in a community-based cohort. J Urol 2000;163:107-13.
6. Rhodes T, Girman CJ, Jacobsen DJ, Roberts RO, Lieber MM, Jacobsen SJ. Longitudinal prostate volume in a community-based sample: 7 year follow up in the Olmsted County Study of urinary symptoms and health status among men. J Urol 2000;163(Suppl 4): 249 [Abstract 1105].
7. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998;338:557-63.
8. Jacobsen SJ, Jacobsen DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158:481-7.
9. Levin RM, Hass MA, Bellamy F, Horan P, Whitbeck K, Chow PH, et al. Effect of oral Tadenan treatment on rabbit bladder structure and function after partial outlet obstruction. J Urol 2002;167(5):2253-9.
10. Girman CJ, Epstein RS, Jacobsen SJ, Guess HA, Panser LA, Oesterling JE, et al. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 1994;44:825-31.
11. Garraway WM, Russell EB, Lee RJ, Collins GN, McKelvie GB, Hehir M, et al. Impact of previously unrecognised benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract 1993;43:318-21.
12. Stewart RB, Moore MT, May FE, Marks RG, Hale WE. Nocturia: a risk factor for falls in the elderly. J Am Geriatr Soc 1992;40:1217-20.
13. Sells H, Donovan J, Ewings P, MacDonagh RP. The development and validation of a quality-of-life measure to assess partner morbidity in benign prostatic enlargement. BJU Int 2000;85:440-5.
14. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999;53:581-9.
15. Roehrborn CG, McConnell JD, Bonilla J, Rosenblatt S, Hudson PB, Malek GH, et al. Serum prostate-specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. J Urol 2000;163:13-20.
16. Roehrborn CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T, et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. Urology 1999;54:662-9.
17. Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, et al. Serum prostate-specific antigen is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 1999;53:473-80.
18. Roehrborn CG, Malice M, Cook TJ, Girman CJ. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001;58:210-6.
19. Boyle P, Robertson C, Wilson T, D'Onofrio A, Benichou J. Risk factors for acute urinary retention in men with benign prostatic hyperplasia. Eur Urol 2003;2:26 [Abstract].
20. Dobrovits M, Chaudry A, Anagnostou T, Bagheri F, Harik M, Marberger M, et al. A longitudinal prospective study of men with mild symptoms of BOO treated with watchful waiting over 4 years. Eur Urol Suppl 2003;2(1):26 [Abstract 96].
21. Sculpher M, Bryan S, Fry P, de Winter P, Payne H, Emberton M. Patients' preferences for the management of non-metastatic prostate cancer: a discrete choice experiment. BMJ 2003 (in press).